AccuStem Sciences, Inc. (ACUT)

Market Cap	2.37M -89.7%
Revenue (ttm)	98.40K
Net Income	-1.65M
EPS	-0.10
Shares Out	16.07M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,826
Open	0.1599
Previous Close	0.1500
Day's Range	0.1475 - 0.1599
52-Week Range	0.1170 - 1.6700
Beta	1.89
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 11, 2026

About AccuStem Sciences

AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. The company offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. It also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. AccuStem Sciences, Inc. was founded in 2013 and is headquartered in New York,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 4
• Stock Exchange: OTCMKTS
• Ticker Symbol: ACUT

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 16, 2026

Data Sources Report a data error